Abstract
Objectives Expanding delivery of oral Pre-exposure Prophylaxis (PrEP) to community pharmacies could improve access, aligning well with government goals for England to eliminate new HIV acquisitions by 2030. Using the Capability, Opportunity, Motivation, Behaviour (COM-B) model for behaviour change, the aim of this research was to explore the barriers and facilitators of community pharmacy PrEP delivery, for pharmacists and community members.
Methods Community members at elevated risk of acquiring HIV and community pharmacists were recruited to participate in semi-structured interviews. Interviews were recorded, transcribed, and thematically analysed within the framework of the COM-B model.
Results 17 interviews with pharmacists (pharmacy owners n=7; employed pharmacists n=6; locums n=4) and 24 with community members (Black African women n=6; other women n=2; young adults aged 18-25 years n=6; transgender people n=6; female sex workers n=4) were carried out. Capability barriers included sub-optimal awareness and knowledge of PrEP, pharmacy facilities, and pharmacist roles in delivering public health services. Opportunity barriers included lack of staff capacity, privacy and pharmacy screening and monitoring facilities. Motivational barriers included a concern that increased access could increase sexually transmitted infections and involve a financial cost. Capability facilitators included awareness raising, HIV and PrEP training and education. Opportunity facilitators included PrEP appointments and the accessibility of pharmacies. Motivational facilitators included a preference for pharmacy delivery over other models (e.g., sexual health, GP), and a belief that it would be discrete and less stigmatising.
Conclusion Pharmacy PrEP delivery is acceptable but for it to be feasible, results point to the need for the development of a behaviour change intervention focusing on education, training and awareness raising, targeting pharmacists and community members to stimulate patient activation and de-stigmatise HIV. This intervention would need to be facilitated by system and environmental changes (e.g., commissioning service).
What is already known on this topic Location, sigma of sexual health clinics and lack of PrEP awareness limits PrEP access for key groups among whom new HIV acquisitions remain high. Previous research and the UK government suggests PrEP provision via community pharmacies as a potential way of improving PrEP access and health equity.
What this study adds This is the first research study to explore the barriers to and facilitators of pharmacy PrEP delivery for pharmacists and community members in the UK. To increase capabilities and motivation, training and awareness raising is needed. To increase opportunities and motivation, environmental and system level changes are needed.
How this study might affect research, practice or policy Results point to the acceptability of pharmacy PrEP delivery, but for it to be feasible behaviour change interventions supported by system and environmental changes are needed.
Competing Interest Statement
RH is an employee of Gilead Sciences Ltd.
Funding Statement
This research was funded by Gilead Sciences Inc and supported by the National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) and the NIHR Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol and NIHR HPRU in Blood Borne and Sexually Transmitted Infections at UCL both in partnership with UK Health Security Agency UKHSA. The views expressed in this article are those of the authors and not necessarily those of the NIHR, UKHSA or the Department of Health and Social Care. CHs time is funded by Gilead Sciences Inc NIHR ARC West and NIHR HPRU in Behavioural Science and Evaluation. HF JH JK are partly funded by NIHR ARC West and NIHR HPRU in Behavioural Science and Evaluation. SDs time is supported by NIHR HPRU in Behavioural Science and Evaluation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Faculty of Health Sciences Research Ethics committee of the University of Bristol gave ethical approval (12833) for the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data underlying this article are available at data-bris.acrc.bris.ac.uk
